RxDoctor Payments Data

William Fritz, MD

Internal Medicine · Washington, MONPI 1407820913

Payments from drug & device makers

$475in general payments, 2019–2025

Across 24 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$129
  • Janssen Scientific Affairs, LLC$107
  • AbbVie$69
  • Novo Nordisk$53
  • Boehringer Ingelheim$31
  • Lilly USA, LLC$29
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475 in reported general payments places this provider in the 60th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$49,791
Medicare patients
145
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$163,242
EliquisApixaban88$94,418
JardianceEmpagliflozin62$76,473
JanuviaSitagliptin Phosphate27$39,346
Repatha SureclickEvolocumab32$29,895
XareltoRivaroxaban30$28,053
RybelsusSemaglutide13$26,825
MounjaroTirzepatide13$23,655
FarxigaDapagliflozin Propanediol17$18,346
LinzessLinaclotide13$14,034
MyrbetriqMirabegron13$11,316
SymbicortBudesonide/Formoterol Fumarate23$10,078
Advair HfaFluticasone Propion/Salmeterol16$8,723
Combivent RespimatIpratropium/Albuterol Sulfate13$6,387
AbrysvoRsv Vacc, Pref A And Pref B/Pf22$6,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$53$190,067124 claims
Boehringer IngelheimJardiance, Combivent Respimat$31$82,86075 claims
MerckJanuvia, Belsomra$129$44,69239 claims
Johnson & JohnsonXarelto$28$28,05330 claims
Lilly USA, LLCMounjaro$29$23,65513 claims
AbbVieLinzess$69$14,03413 claims
GSKArexvy$12$4,59319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →